Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of “Hold” from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus rating of “Hold” by the twenty-two ratings firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $17.00.

Several equities analysts have recently issued reports on NTLA shares. William Blair downgraded Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. Bank of America reduced their price target on Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Oppenheimer set a $27.00 price target on Intellia Therapeutics in a report on Friday, November 7th. Finally, Wall Street Zen raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 10th.

Insider Activity

In other news, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. The trade was a 3.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP James Basta sold 10,397 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares in the company, valued at $935,072.88. This represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC bought a new position in Intellia Therapeutics during the 2nd quarter worth approximately $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $30,000. Caitong International Asset Management Co. Ltd bought a new position in Intellia Therapeutics during the third quarter worth $30,000. Whipplewood Advisors LLC raised its stake in Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after buying an additional 3,447 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in Intellia Therapeutics in the third quarter valued at $33,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Up 2.4%

Shares of NASDAQ:NTLA opened at $12.02 on Thursday. The company has a market cap of $1.39 billion, a PE ratio of -2.81 and a beta of 2.05. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The firm has a 50-day simple moving average of $9.36 and a 200 day simple moving average of $12.74.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.10. The firm had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period last year, the company earned ($1.34) earnings per share. As a group, research analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.